Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Venrock Healthcare Capital Par Purchases 88,794 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par bought 88,794 shares of the company’s stock in a transaction dated Friday, February 14th. The stock was purchased at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the transaction, the insider now directly owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. This represents a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par acquired 8,971 shares of Oruka Therapeutics stock. The stock was purchased at an average cost of $11.86 per share, for a total transaction of $106,396.06.
• On Monday, February 10th, Venrock Healthcare Capital Par acquired 574 shares of Oruka Therapeutics stock. The shares were purchased at an average price of $10.90 per share, with a total value of $6,256.60.

Oruka Therapeutics Stock Down 9.2 %

Oruka Therapeutics stock traded down $0.97 during mid-day trading on Thursday, hitting $9.56. 414,591 shares of the stock were exchanged, compared to its average volume of 292,147. The firm has a market capitalization of $334.59 million, a PE ratio of -1.53 and a beta of 0.77. Oruka Therapeutics, Inc. has a 12 month low of $9.53 and a 12 month high of $53.88. The firm’s fifty day moving average price is $14.72.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ORKA shares. Wedbush reiterated an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, February 7th. Finally, Wolfe Research initiated coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price for the company. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics currently has a consensus rating of “Buy” and an average price target of $39.86.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of ORKA. Jefferies Financial Group Inc. bought a new stake in Oruka Therapeutics during the fourth quarter valued at $6,787,000. Toronto Dominion Bank acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $1,131,000. Frazier Life Sciences Management L.P. lifted its stake in shares of Oruka Therapeutics by 22.2% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 583,327 shares of the company’s stock valued at $11,311,000 after purchasing an additional 106,000 shares during the period. VR Adviser LLC boosted its position in shares of Oruka Therapeutics by 6.5% during the 4th quarter. VR Adviser LLC now owns 3,285,620 shares of the company’s stock valued at $63,708,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $236,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.